PS070 Rosuvastatin Dose-Dependently Improves Flow-Mediated Dilation, but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients
Genetic analysis from patients participated in the randomized trials reported that the increased risk of type 2 diabetes noted with statins is at least partially explained by HMG-coenzyme A reductase inhibition.
Source: CVD Prevention and Control - Category: Global & Universal Authors: K. Koh Tags: Poster Abstract Source Type: research
More News: Cholesterol | Crestor | Diabetes | Diabetes Type 2 | Endocrinology | Genetics | Insulin | International Medicine & Public Health | Rosuvastatin | Statin Therapy